Study of Fremanezumab in Patients With Interstitial Cystitis-Bladder Pain Syndrome

Study Title
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
Teva Identifier
TV48125-CNS-20022
ClinicalTrials.gov Identifier
NCT04447729
Study Status
Withdrawn
Trial Condition(s)
Interstitial Cystitis
Interventions
Drug: fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female
Age Range
18 Years and older
Trial Duration
October 15, 2020 - February 10, 2022
Phase
Phase 2

Study Type

Interventional